|View printer-friendly version|
|December 09, 2005 1:08 p.m.|
|Teva Announces Approval of Cefprozil Tablets and Cefprozil for Oral Suspension Usp|
Jerusalem, Israel, December 9, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's ANDAs for Cefprozil Tablets USP, 250 mg and 500 mg and Cefprozil for Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL. Shipment of these products is expected to commence upon expiry of brand exclusivity later this month.